“Pfizer reports that the majority of the production lines at the medicine manufacturing facility that was severely damaged by a tornado two months ago have started up again.”
Pfizer reports that the majority of the production lines at the medicine manufacturing facility that was severely damaged by a tornado two months ago have started up again. However, until at least the middle of 2024, there might still be a scarcity of some pharmaceuticals from the plant.
According to Pfizer, its Rocky Mount, North Carolina plant is still recovering and is anticipated to restore full operations by the end of the year.
Production Capacity of Pfizer’s Carolina Plant-
Nearly 8% of all sterile injectable medications used in hospitals across the US are supplied by the Rocky Mount factory. Anaesthesia, analgesia, therapeutics, anti-infectives, and neuromuscular blockers are some of them. Additionally, the facility produces about 25% of the company’s pharmaceuticals in this area. Pfizer alerted hospitals in August that the supply of several medications would be interrupted.
The American Society of Health-System Pharmacists database indicated a lack of a certain injectable from a plant as of last month. This sodium chloride injection is used to replenish lost salt and water levels in the body as a result of specific medical disorders.
Pfizer Resumes Its Drug Production, but at Slow Rate-
On Monday, Pfizer revealed that it has restarted manufacture of 13 important medications that had been ranked according to patient need and stock levels. The identities of these medications weren’t made public by the corporation, though.
Pfizer states that they are still monitoring emergency requests for particular drugs made at the Rocky Mount site. In order to handle the distribution of 12 medications that are thought to be in high demand for medical purposes, the business established an emergency ordering mechanism in August.
In the middle of the continuous problem of drug shortages in the US, Pfizer recently made a statement. Numerous drugs, including ADHD meds, painkillers, and injectable cancer therapies, are affected by these shortages. These shortages are caused, among other things, by issues with manufacturing quality control and rising demand.